Search research articles
Contact Us
Filters
Showing results (21-30 of 150) with videos related to
Page
of 15
Sort By:
Nature Reviews. Clinical Oncology
|
May 16, 2018
Low-value approvals and high prices might incentivize ineffective drug development
Vinay Prasad, Christopher McCabe, Sham Mailankody
Pharmacoeconomics
|
November 14, 2009
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected
Allan Wailoo, Aki Tsuchiya, Christopher McCabe
Pharmacoeconomics
|
March 7, 2014
Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?
Mike Paulden, Christopher McCabe, Jonathan Karnon
Trends in Cancer
|
August 29, 2018
Balancing the Economics and Ethics of Personalised Oncology
Nicola Flaum, Peter Hall, Christopher McCabe
BMJ (Clinical Research Ed.)
|
October 29, 2005
Orphan drugs and the NHS: should we value rarity?
Christopher McCabe, Karl Claxton, Aki Tsuchiya
Nature Reviews. Clinical Oncology
|
November 14, 2018
Addendum: Low-value approvals and high prices might incentivize ineffective drug development
Vinay Prasad, Christopher McCabe, Sham Mailankody
Pharmacoeconomics
|
September 5, 2008
The NICE cost-effectiveness threshold: what it is and what that means
Christopher McCabe, Karl Claxton, Anthony J Culyer
Pharmacoeconomics
|
December 13, 2016
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
Mike Paulden, James F O'Mahony, Christopher McCabe
Physical Review Letters
|
September 22, 2018
Directly Detecting Sub-GeV Dark Matter with Electrons from Nuclear Scattering
Matthew J Dolan, Felix Kahlhoefer, Christopher McCabe
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Use of visual analog scales in economic evaluation
John Brazier, Colin Green, Christopher McCabe, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 150) with videos related to
Sort By:
Page
of 15
Nature Reviews. Clinical Oncology
|
May 16, 2018
Low-value approvals and high prices might incentivize ineffective drug development
Vinay Prasad, Christopher McCabe, Sham Mailankody
Pharmacoeconomics
|
November 14, 2009
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected
Allan Wailoo, Aki Tsuchiya, Christopher McCabe
Pharmacoeconomics
|
March 7, 2014
Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?
Mike Paulden, Christopher McCabe, Jonathan Karnon
Trends in Cancer
|
August 29, 2018
Balancing the Economics and Ethics of Personalised Oncology
Nicola Flaum, Peter Hall, Christopher McCabe
BMJ (Clinical Research Ed.)
|
October 29, 2005
Orphan drugs and the NHS: should we value rarity?
Christopher McCabe, Karl Claxton, Aki Tsuchiya
Nature Reviews. Clinical Oncology
|
November 14, 2018
Addendum: Low-value approvals and high prices might incentivize ineffective drug development
Vinay Prasad, Christopher McCabe, Sham Mailankody
Pharmacoeconomics
|
September 5, 2008
The NICE cost-effectiveness threshold: what it is and what that means
Christopher McCabe, Karl Claxton, Anthony J Culyer
Pharmacoeconomics
|
December 13, 2016
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
Mike Paulden, James F O'Mahony, Christopher McCabe
Physical Review Letters
|
September 22, 2018
Directly Detecting Sub-GeV Dark Matter with Electrons from Nuclear Scattering
Matthew J Dolan, Felix Kahlhoefer, Christopher McCabe
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Use of visual analog scales in economic evaluation
John Brazier, Colin Green, Christopher McCabe, et al.
Page
of 15